PTC Inc

PTC Inc. boosts shareholder value with dividends, unveils cloud‑native CAD/PLM for automotive and regulated markets, driving compliance‑ready manufacturing.

PTC Inc. keeps growing its discrete‑manufacturing software, leveraging Windchill PLM, ThingWorx IoT, ML and digital twins to boost time‑to‑market, efficiency and compliance—watch for next‑quarter earnings to gauge adoption and revenue upside.

PTC Inc. expands into India’s renewable‑energy market, pairing its digital twins and IoT tech with NLC India Renewables to develop up to 2,000 MW of clean power projects, boosting diversification and positioning the firm at the tech‑energy frontier.

PTC Inc. unveils an AI engine to boost product lifecycle and quality‑management, while PTC Therapeutics gains Health Canada approval for Sephience™—a rare‑disease drug for PKU, signaling a dual‑front tech and pharma expansion.

PTC Inc. is trading near its 12‑month midpoint—stable but premium. Explore how its strong EBITDA, digital‑twin gaps, and AI opportunities weigh against regulatory risks and fierce competition.

PTC Inc. has announced a series of strategic milestones across various technology sectors, including security, CAD, warranty management, and defense, solidifying its position as a diversified and innovative global technology solutions provider.

PTC Inc. has experienced a 146% increase in market value over the last five years, driven by its robust position in the Product Lifecycle Management (PLM) ecosystem, which is forecasted to grow at a 7.4% compound annual growth rate from 2026 to 2032.

PTC Inc. is poised for continued growth, with its stock value more than doubling from its 52-week low and industry analysts predicting a significant increase in its stock value over the next three years.

PTC Inc.’s stock price surged significantly after securing a major contract worth over ₹100 crore from BrahMos Aerospace for the supply of titanium castings.

PTC Inc’s stock price has declined after the FDA rejected its oral drug for a rare genetic disorder, citing efficacy concerns.